Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions

A systematic review and meta-analysis

Allison Low, Ambar Faridi, Kavita Bhavsar, Glenn C. Cockerham, Michele Freeman, Rongwei (Rochelle) Fu, Robin Paynter, Karli Kondo, Devan Kansagara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular conditions but the benefits and harms of these treatments are uncertain. We conducted a systematic review to compare the effects of aflibercept, bevacizumab and ranibizumab on best-corrected visual acuity (BCVA) changes, quality of life and ocular or systemic adverse events in patients with neovascular age-related macular degeneration (NVAMD), diabetic macular oedema (DME) and central or branch retinal vein occlusion (RVO). We searched published and unpublished literature sources to February 2017 for randomised controlled trials and cohort or modelling studies reporting comparative costs in the USA. Two reviewers extracted data and graded the strength of the evidence using established methods. Of 17 included trials, none reported a clinically important difference (≥ 5 letters) in visual acuity gains between agents. Nine trials provide high-strength evidence of no difference between bevacizumab and ranibizumab for NVAMD. Three trials provide moderate-strength evidence of no difference between bevacizumab and ranibizumab for DME. There was low-strength evidence of similar effects between aflibercept and ranibizumab for NVAMD, aflibercept and bevacizumab for RVO and all three agents for DME. There was insufficient evidence to compare bevacizumab and ranibizumab for RVO. Rates of ocular adverse events were low, and systemic harms were generally similar between groups, although 1 DME trial reported more arterial thrombotic events with ranibizumab versus aflibercept. Overall, no agent had a clear advantage over another for effectiveness or safety. Aflibercept and ranibizumab were significantly less cost-effective than repackaged bevacizumab in two trials. Systematic review registration number: CRD42016034076.

Original languageEnglish (US)
JournalBritish Journal of Ophthalmology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Endothelial Growth Factors
Meta-Analysis
Macular Edema
Retinal Vein Occlusion
Macular Degeneration
Visual Acuity
Costs and Cost Analysis
Ranibizumab
Vascular Endothelial Growth Factor A
Bevacizumab
Randomized Controlled Trials
Quality of Life
aflibercept
Safety

Keywords

  • aflibercept
  • age-related macular degeneration
  • Anti-VEGF therapy
  • bevacizumab
  • central or branch retinal vein occlusion
  • diabetic macular edema
  • ranibizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions : A systematic review and meta-analysis. / Low, Allison; Faridi, Ambar; Bhavsar, Kavita; Cockerham, Glenn C.; Freeman, Michele; Fu, Rongwei (Rochelle); Paynter, Robin; Kondo, Karli; Kansagara, Devan.

In: British Journal of Ophthalmology, 01.01.2018.

Research output: Contribution to journalArticle

@article{5a73e2d065e8428386bb4e010909a09b,
title = "Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: A systematic review and meta-analysis",
abstract = "Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular conditions but the benefits and harms of these treatments are uncertain. We conducted a systematic review to compare the effects of aflibercept, bevacizumab and ranibizumab on best-corrected visual acuity (BCVA) changes, quality of life and ocular or systemic adverse events in patients with neovascular age-related macular degeneration (NVAMD), diabetic macular oedema (DME) and central or branch retinal vein occlusion (RVO). We searched published and unpublished literature sources to February 2017 for randomised controlled trials and cohort or modelling studies reporting comparative costs in the USA. Two reviewers extracted data and graded the strength of the evidence using established methods. Of 17 included trials, none reported a clinically important difference (≥ 5 letters) in visual acuity gains between agents. Nine trials provide high-strength evidence of no difference between bevacizumab and ranibizumab for NVAMD. Three trials provide moderate-strength evidence of no difference between bevacizumab and ranibizumab for DME. There was low-strength evidence of similar effects between aflibercept and ranibizumab for NVAMD, aflibercept and bevacizumab for RVO and all three agents for DME. There was insufficient evidence to compare bevacizumab and ranibizumab for RVO. Rates of ocular adverse events were low, and systemic harms were generally similar between groups, although 1 DME trial reported more arterial thrombotic events with ranibizumab versus aflibercept. Overall, no agent had a clear advantage over another for effectiveness or safety. Aflibercept and ranibizumab were significantly less cost-effective than repackaged bevacizumab in two trials. Systematic review registration number: CRD42016034076.",
keywords = "aflibercept, age-related macular degeneration, Anti-VEGF therapy, bevacizumab, central or branch retinal vein occlusion, diabetic macular edema, ranibizumab",
author = "Allison Low and Ambar Faridi and Kavita Bhavsar and Cockerham, {Glenn C.} and Michele Freeman and Fu, {Rongwei (Rochelle)} and Robin Paynter and Karli Kondo and Devan Kansagara",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/bjophthalmol-2018-312691",
language = "English (US)",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions

T2 - A systematic review and meta-analysis

AU - Low, Allison

AU - Faridi, Ambar

AU - Bhavsar, Kavita

AU - Cockerham, Glenn C.

AU - Freeman, Michele

AU - Fu, Rongwei (Rochelle)

AU - Paynter, Robin

AU - Kondo, Karli

AU - Kansagara, Devan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular conditions but the benefits and harms of these treatments are uncertain. We conducted a systematic review to compare the effects of aflibercept, bevacizumab and ranibizumab on best-corrected visual acuity (BCVA) changes, quality of life and ocular or systemic adverse events in patients with neovascular age-related macular degeneration (NVAMD), diabetic macular oedema (DME) and central or branch retinal vein occlusion (RVO). We searched published and unpublished literature sources to February 2017 for randomised controlled trials and cohort or modelling studies reporting comparative costs in the USA. Two reviewers extracted data and graded the strength of the evidence using established methods. Of 17 included trials, none reported a clinically important difference (≥ 5 letters) in visual acuity gains between agents. Nine trials provide high-strength evidence of no difference between bevacizumab and ranibizumab for NVAMD. Three trials provide moderate-strength evidence of no difference between bevacizumab and ranibizumab for DME. There was low-strength evidence of similar effects between aflibercept and ranibizumab for NVAMD, aflibercept and bevacizumab for RVO and all three agents for DME. There was insufficient evidence to compare bevacizumab and ranibizumab for RVO. Rates of ocular adverse events were low, and systemic harms were generally similar between groups, although 1 DME trial reported more arterial thrombotic events with ranibizumab versus aflibercept. Overall, no agent had a clear advantage over another for effectiveness or safety. Aflibercept and ranibizumab were significantly less cost-effective than repackaged bevacizumab in two trials. Systematic review registration number: CRD42016034076.

AB - Intravitreal antivascular endothelial growth factor (VEGF) agents are widely used to treat ocular conditions but the benefits and harms of these treatments are uncertain. We conducted a systematic review to compare the effects of aflibercept, bevacizumab and ranibizumab on best-corrected visual acuity (BCVA) changes, quality of life and ocular or systemic adverse events in patients with neovascular age-related macular degeneration (NVAMD), diabetic macular oedema (DME) and central or branch retinal vein occlusion (RVO). We searched published and unpublished literature sources to February 2017 for randomised controlled trials and cohort or modelling studies reporting comparative costs in the USA. Two reviewers extracted data and graded the strength of the evidence using established methods. Of 17 included trials, none reported a clinically important difference (≥ 5 letters) in visual acuity gains between agents. Nine trials provide high-strength evidence of no difference between bevacizumab and ranibizumab for NVAMD. Three trials provide moderate-strength evidence of no difference between bevacizumab and ranibizumab for DME. There was low-strength evidence of similar effects between aflibercept and ranibizumab for NVAMD, aflibercept and bevacizumab for RVO and all three agents for DME. There was insufficient evidence to compare bevacizumab and ranibizumab for RVO. Rates of ocular adverse events were low, and systemic harms were generally similar between groups, although 1 DME trial reported more arterial thrombotic events with ranibizumab versus aflibercept. Overall, no agent had a clear advantage over another for effectiveness or safety. Aflibercept and ranibizumab were significantly less cost-effective than repackaged bevacizumab in two trials. Systematic review registration number: CRD42016034076.

KW - aflibercept

KW - age-related macular degeneration

KW - Anti-VEGF therapy

KW - bevacizumab

KW - central or branch retinal vein occlusion

KW - diabetic macular edema

KW - ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=85056417297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056417297&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2018-312691

DO - 10.1136/bjophthalmol-2018-312691

M3 - Article

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

ER -